Traditional Chinese medicine composition for treating interstitial lung disease as well as preparation method and application of traditional Chinese medicine composition

Abstract

The invention relates to the technical field of medicines for treating interstitial lung diseases, in particular to a traditional Chinese medicine composition for treating interstitial lung diseases as well as a preparation method and application of the traditional Chinese medicine composition. Comprising the following raw materials in parts by weight: 50 to 150 parts of radix angelicae sinensis, 100 to 200 parts of flos carthami, 100 to 300 parts of radix rehmanniae, 100 to 300 parts of radix salviae miltiorrhizae, 100 to 300 parts of radix adenophorae, 100 to 300 parts of radix glehniae, 100 to 200 parts of radix ophiopogonis, 100 to 300 parts of radix rehmanniae preparata, 100 to 300 parts of roasted rhizoma atractylodis macrocephalae, 50 to 150 parts of liquorice root, 100 to 300 parts of semen benincasae, 100 to 300 parts of rhizoma polygoni cuspidati, 100 to 200 parts of semen persicae and 100 to 300 parts of herba houttuyniae. The traditional Chinese medicine composition disclosed by the invention is used for comprehensively conditioning pathogenesis of interstitial lung diseases and flaccid lung diseases through a reasonable compatibility principle, has various effects of promoting blood circulation to remove blood stasis, nourishing yin and moisturizing lung, invigorating spleen and replenishing qi, clearing away heat and toxic materials and the like, and can be used for more effectively treating related diseases such as interstitial lung diseases in combination with a traditional Chinese medicine iontophoresis instrument.

Description

Technical Field

[0001] The present invention relates to the technical field of interstitial lung disease therapeutic drugs, and in particular to a Chinese medicine composition for treating interstitial lung disease, and a preparation method and application thereof. Background Art

[0002] Interstitial lung disease is one of the most serious complications associated with connective tissue disease. Its incidence has been gradually increasing in recent years. It includes more than 200 types of diseases with different causes. Its main pathological changes are increased interstitial cells and matrix components, inflammatory cell infiltration, tissue cell reaction, and alveolar epithelial cell hyperplasia and metaplasia. Its main clinical manifestations are progressive exertional shortness of breath, restrictive ventilation dysfunction with reduced diffusion function, diffuse bilateral lung lesions in the impact, and eventually develop into diffuse pulmonary fibrosis and honeycomb lung, which leads to respiratory failure and death.

[0003] Modern medicine has limited treatment options for interstitial lung disease, especially for patients with Qi and Yin deficiency and blood stasis. Glucocorticoids combined with immunosuppressants are often used for treatment. However, these drugs are often accompanied by significant toxicity and side effects during treatment, such as decreased immune function and increased risk of infection, which limits their long-term application effects.

[0004] Traditional Chinese medicine has accumulated rich experience in the treatment of interstitial lung disease, especially in regulating qi and blood, balancing yin and yang, and strengthening the body and eliminating evil. Traditional Chinese medicine believes that interstitial lung disease is mostly caused by dysfunction of the lungs, spleen, and kidneys, leading to deficiency of both qi and yin, phlegm and blood stasis, and obstruction of the lung network. Among them, "deficiency" is the internal factor of the disease, while "stasis, phlegm, and poison" are the key pathological factors that damage the lung network. Therefore, the treatment of interstitial lung disease needs to start from regulating the internal organs, nourishing qi and yin, and removing blood stasis and unblocking the collaterals.

[0005] Although Chinese medicine has a certain effect in treating interstitial lung disease, it also has some shortcomings, such as limited drug types, inconsistent efficacy, long treatment cycle, lack of large-scale clinical research, complex drug ingredients, and limited reversal of pulmonary fibrosis changes. Therefore, when treating interstitial lung disease, the patient's condition, constitution and treatment needs should be comprehensively considered to select the appropriate treatment method. At the same time, patients should also receive standardized treatment under the guidance of a doctor to obtain the best treatment effect.

[0006] In view of this, the present invention is proposed. Summary of the invention

[0007] The purpose of the present invention is to provide a Chinese medicine composition for treating interstitial lung disease, and a preparation method and application thereof. The Chinese medicine composition comprehensively regulates the pathogenesis of interstitial lung disease and pulmonary emphysema through reasonable compatibility principles, has multiple effects such as promoting blood circulation and removing blood stasis, nourishing yin and moistening the lungs, strengthening the spleen and replenishing qi, clearing away heat and detoxifying, and can more effectively treat interstitial lung disease and other related diseases.

[0008] In a first aspect, the present invention provides a Chinese medicine composition comprising the following raw materials in parts by weight:

[0009] 50-150 parts of angelica sinensis, 100-300 parts of raw rehmannia, 100-300 parts of salvia miltiorrhiza, 100-300 parts of adenophora australis, 100-300 parts of northern adenophora, 100-200 parts of ophiopogon japonicus, 100-300 parts of cooked rehmannia, 100-300 parts of stir-fried atractylodes, 50-150 parts of liquorice, 100-300 parts of wax gourd seeds, 100-300 parts of knotweed, and 100-200 parts of peach kernel.

[0010] Angelica: It tastes sweet and spicy, is warm in nature, and enters the liver, heart, and spleen meridians. Angelica not only has the effect of nourishing blood, but also can promote blood circulation and remove blood stasis; it can have a good therapeutic effect on joint pain caused by internal blood stasis, rheumatism, and injuries; it can promote intestinal peristalsis and improve intestinal function; it can dispel cold and relieve pain, and has significant effects on the treatment of pain syndromes such as injuries, rheumatism, and injuries; it can treat neurological diseases such as stroke.

[0011] Shengdi: It tastes sweet, bitter and cold, and enters the heart, liver and kidney meridians. It can clear heat and toxins from the body and relieve various symptoms caused by heat and toxins, such as high fever, thirst, irritability, etc.; it has the effect of nourishing yin and moistening dryness, and can promote the production of yin fluid in the body, and improve symptoms such as dry mouth, thirst and polydipsia caused by yin deficiency; Shengdi also has multiple effects such as sedation, anti-inflammatory, anti-allergic, and immune enhancement.

[0012] Salvia miltiorrhiza: It tastes bitter and slightly cold, and enters the heart and liver meridians. It can dilate blood vessels, increase blood flow, and improve microcirculation, thereby achieving the effect of promoting blood circulation and removing blood stasis. Salvia miltiorrhiza can clear heart fire, and has a good alleviating effect on symptoms such as palpitations and insomnia caused by excessive heart fire. Salvia miltiorrhiza can also inhibit inflammatory reactions, and has a certain therapeutic effect on cardiac inflammatory diseases such as myocarditis and endocarditis. Salvia miltiorrhiza also has many modern pharmacological effects such as anti-arrhythmia, regulating blood lipids, anti-atherosclerosis, and protecting myocardial cells.

[0013] Adenophora australis: It is sweet, slightly bitter, and slightly cold in nature. It enters the lung and stomach meridians. It can nourish lung yin and clear away lung heat. It has significant therapeutic effects on symptoms such as dry cough, chronic cough due to lung deficiency, and dry cough with little sputum. Its sweet, moist and slightly cold properties allow it to nourish the lung yin while also moistening the lungs and clearing away lung heat, making it an important medicine for treating lung yin deficiency. It also has the effects of nourishing stomach yin and clearing away stomach heat, and has a good therapeutic effect on symptoms such as dry mouth and throat, constipation, poor appetite and vomiting caused by insufficient stomach yin. It can nourish stomach yin, promote the secretion of gastric juice, and enhance the digestive function of the stomach, thereby improving the above symptoms. It also has the effect of resolving phlegm, and has a good therapeutic effect on symptoms such as dry lung and sticky phlegm, and difficulty in coughing up phlegm. Its phlegm-resolving effect complements the effects of nourishing yin and clearing the lungs, and together they play a role in treating lung diseases. It can replenish positive energy and enhance the body's resistance. When treating deficiency syndromes such as lung deficiency and stomach deficiency, the qi-invigorating effect of it can enhance physical fitness and promote recovery from the disease. In addition, it has many other effects such as clearing away heat and detoxifying, strengthening tendons and bones, and improving immunity.

[0014] Northern Glehnia littoralis: It tastes sweet and slightly bitter, is slightly cold in nature, and belongs to the lung and stomach meridians. It has the effect of nourishing yin and moistening dryness, helps to moisturize the yin fluid in the body, and improves the symptoms of yin deficiency. It is used to treat dry coughs and lung diseases, can moisturize the lung mucosa, relieve coughs and throat discomfort, especially in cold and dry seasons or dry environments. It has significant effects; the polysaccharides and flavonoids it contains have antioxidant and anti-inflammatory properties, which help to improve the body's ability to fight infection and disease; Northern Glehnia littoralis also has the effects of benefiting the stomach and promoting fluid production, nourishing yin and benefiting the kidneys.

[0015] Ophiopogon japonicus: sweet, slightly bitter, slightly cold in nature, enters the lung, heart, and stomach meridians, can nourish yin fluid, relieve symptoms of yin deficiency, restore the balance of yin fluid in the body, thereby improving the body's moisture; has a calming and tranquilizing effect, and can be used to relieve anxiety, insomnia, and nervous tension; can nourish yin and produce body fluid, and has a good effect on symptoms such as lack of body fluid, thirst, dry cough and hemoptysis caused by lung and stomach yin deficiency; it contains a variety of anti-inflammatory and antioxidant ingredients, which help to reduce inflammation and slow down cell aging.

[0016] Rehmannia glutinosa: sweet in taste, slightly warm in nature, enters the liver and kidney meridians, can nourish yin fluid, replenish blood, improve symptoms of blood deficiency such as pale complexion, dizziness, palpitations, etc.; it can also nourish blood and calm the mind, and has a certain alleviating effect on symptoms such as insomnia, dreaminess, palpitations and forgetfulness; it contains a variety of natural antioxidants and anti-inflammatory substances, which help to scavenge free radicals, reduce inflammatory reactions, and maintain physical health. At the same time, it can also play a certain protective role on the liver and kidneys, help regulate liver and kidney function, and promote detoxification and metabolism.

[0017] Stir-fried Atractylodes macrocephala: bitter and sweet in taste, warm in nature, enters the spleen and stomach meridians, can tonify spleen qi, promote the functioning of spleen and stomach, adjust spleen and stomach motor function, thereby improving the symptoms of spleen deficiency; has the effect of drying dampness and promoting diuresis, can assist in the treatment of spleen deficiency and fluid retention; has the effect of tonifying the middle and replenishing qi, can enhance the body's physical strength and resistance, improve symptoms such as fatigue, dizziness, palpitations, etc.; also has multiple functions such as anti-gastric ulcer, enhancing the body's immunity, and increasing the body's immune ability against bacterial phagocytosis, and improves the body's health through multiple ways.

[0018] Licorice: sweet in taste, neutral in nature, enters the heart meridian, lung meridian, spleen meridian, and stomach meridian. It can nourish the spleen and replenish qi, enhance the transportation and transformation function of the spleen and stomach, thereby improving symptoms such as spleen and stomach weakness, fatigue, palpitations and shortness of breath; it has the effect of clearing away heat and detoxifying, and can treat carbuncles, sores, sore throats and other hot and toxic diseases; it has a significant expectorant and cough-relieving effect, and can treat symptoms such as cough, sputum, and asthma caused by diseases such as bronchitis and emphysema; in addition, licorice can also reduce the detoxification effect of other Chinese medicines, reconcile the potency of various medicines, prevent adverse reactions caused by interactions between drugs, and protect organs such as the liver from damage by drug toxicity.

[0019] Winter melon seeds: cool in nature, sweet and light in taste, belong to the lung meridian and large intestine meridian, can clear heat and toxins in the body, relieve cough and sputum caused by heat and toxins, and improve the health of the respiratory system; it has the effects of moistening the lungs and relieving coughs, promoting immune function, etc. It can moisturize the lungs, improve blood circulation in the lungs, and prevent the occurrence of lung diseases; at the same time, winter melon seeds also have a good conditioning effect on the large intestine, can promote large intestine peristalsis, help digestion, and prevent constipation; in addition, winter melon seeds also have modern pharmacological effects such as anti-pulmonary fibrosis and promoting immune function.

[0020] Polygonum cuspidatum: It is slightly bitter and slightly cold in nature, and enters the liver meridian, gallbladder meridian and lung meridian; it can reduce the heat evil in the body and eliminate toxins, and has significant therapeutic effects on carbuncles, sores, sore throat and other hot and toxic diseases; the active ingredients it contains, such as resveratrol, can inhibit platelet aggregation, improve microcirculation, and thus exert the effect of promoting blood circulation and removing blood stasis; certain compounds in Polygonum cuspidatum also have the effect of calming the central nervous system and relaxing bronchial smooth muscles, and can relieve the symptoms of respiratory diseases such as cough and asthma.

[0021] Peach kernel: It is mild in nature, bitter and sweet in taste, and enters the heart, liver, and large intestine meridians. It has a powerful effect of promoting blood circulation and removing blood stasis. It can promote blood circulation, eliminate blood stasis, and help relieve various symptoms caused by blood stasis. Peach kernel contains amygdalin, which has an antitussive and antiasthmatic effect, and can relieve symptoms such as cough and asthma. Peach kernel also has a certain anti-inflammatory and analgesic effect, which can reduce swelling and pain caused by inflammation.

[0022] The Chinese medicine composition of the present invention comprehensively regulates the pathogenesis of interstitial lung disease and pulmonary emphysema through reasonable compatibility principles, and has multiple effects such as promoting blood circulation and removing blood stasis, nourishing yin and moistening the lungs, strengthening the spleen and replenishing qi, clearing away heat and detoxifying. At the same time, combined with the use of a Chinese medicine ion introduction instrument, it can more effectively treat interstitial lung disease and other related diseases.

[0023] As a preferred embodiment of the present technical solution, the Chinese medicine composition of the present invention further comprises the following raw materials in parts by weight: 100-200 parts of safflower, 100-300 parts of houttuynia cordata, 100-300 parts of honey, 50-150 parts of crystal sugar and 100-200 parts of donkey-hide gelatin.

[0024] Safflower: It tastes spicy and is warm in nature. It enters the heart and liver meridians. It has the effects of promoting blood circulation, removing blood stasis, regulating menstruation and relieving pain. The antioxidants it contains, such as flavonoids and carotenoids, help fight damage from free radicals and slow down the cell aging process. Safflower also has a sedative effect, helps relax the body and promote sleep, and is used to relieve anxiety and improve sleep quality. External use of safflower can promote blood circulation and remove phlegm, promote blood circulation, warm the meridians, dispel cold and relieve pain, and treat symptoms such as bruises and swelling of the lower limbs, cold lower limbs, vasculitis, and dysmenorrhea caused by uterine cold.

[0025] Houttuynia cordata: It tastes spicy and is cold in nature. It belongs to the lung meridian. Houttuynia cordata is cold in nature and is good at clearing away lung heat. It can effectively remove heat and toxins from the body and has significant therapeutic effects on symptoms such as lung heat cough, phlegm heat and cough. Houttuynia cordata can enhance the body's immunity and improve the phagocytic ability of white blood cells, thereby enhancing the body's resistance to infectious diseases. Houttuynia cordata also has multiple effects such as analgesia, antitussive, hemostasis, inhibition of serous secretion, promotion of tissue regeneration and wound healing. It can be used to treat respiratory diseases such as lung abscess, chronic bronchitis, obstructive pulmonary emphysema, as well as other diseases such as hemorrhoids, rectal prolapse, skin diseases, etc.

[0026] Honey is sweet and neutral in nature. It enters the lung, spleen, and large intestine meridians. It has the effect of tonifying the middle and relieving urgency. It can also help relieve coughs caused by lung heat or lung dryness. Rock sugar is sweet and neutral in nature. It enters the spleen and stomach meridians. It has the effect of tonifying the middle and replenishing qi. It can assist other medicines to nourish the body and enhance physical strength. Donkey-hide gelatin is made from donkey skin. It is sweet and neutral in nature. It enters the lung, liver, and kidney meridians. It has the effect of tonifying blood and yin, moistening dryness and stopping bleeding, and can improve symptoms such as dry cough and hemoptysis.

[0027] As a preferred embodiment of the present technical solution, the Chinese medicine composition of the present invention comprises the following raw materials in parts by weight:

[0028] 150 parts of angelica, 100 parts of safflower, 100 parts of raw rehmannia, 100 parts of salvia miltiorrhiza, 300 parts of adenophora australis, 300 parts of northern adenophora, 100 parts of ophiopogon, 100 parts of cooked rehmannia, 100 parts of stir-fried atractylodes, 100 parts of liquorice, 300 parts of wax gourd seeds, 150 parts of knotweed, 100 parts of peach kernel, 150 parts of houttuynia cordata, 100 parts of donkey-hide gelatin, 200 parts of honey and 150 parts of crystal sugar.

[0029] In a second aspect, the present invention also discloses the use of the above-mentioned Chinese medicine composition in the preparation of an anti-lung disease medicament, wherein the anti-lung disease includes but is not limited to interstitial lung disease, and the medicament includes drugs and health products for auxiliary treatment of interstitial lung disease.

[0030] As a preferred embodiment of the present technical solution, the types of the medicament include decoctions, suspensions, pastes, granules, pills, powders, tablets or capsules, and the types of the medicament of the present invention are not strictly limited.

[0031] In a third aspect, the present invention further provides a method for preparing a lung-wasting ointment using the above-mentioned Chinese medicine combination, which should also fall within the protection scope of the present invention. The method specifically comprises the following steps:

[0032] S1, soaking angelica, safflower, raw rehmannia, salvia miltiorrhiza, adenophora australis, adenophora scabra, ophiopogon japonicus, cooked rehmannia, stir-fried atractylodes macrocephala, liquorice, wax gourd seeds, knotweed, peach kernel and houttuynia cordata in water, decocting, concentrating and filtering to obtain a clear paste;

[0033] S2, adding melted ajiao and refined honey to the clear paste, collecting the paste and adding crystal sugar to obtain a paste;

[0034] S3. Add the paste into the paste packaging machine and divide it into packages to obtain the pulmonary tuberculosis paste.

[0035] As a preferred embodiment of the present technical solution, during the soaking, water is added to the Chinese medicinal materials until it exceeds the liquid surface of the medicinal materials by 3-5 cm and then soaked for 10-15 hours to soften the Chinese medicinal materials and improve the extraction effect of the effective ingredients in the Chinese medicinal materials;

[0036] During the decoction, the soaked medicinal materials are decocted together with the soaking water, the residue is filtered to obtain the medicinal juice 1-1.5 hours after boiling, water is added to the residue until the medicinal surface, the medicinal juice is obtained 1-1.5 hours after boiling, and the two medicinal juices are mixed; the mixed medicinal juice is allowed to stand and sieved, and the obtained filtrate is concentrated to 1000mL, centrifuged and filtered, and then concentrated to obtain a clear paste with a relative density of 1.21-1.25. Through multiple decoctions, it is ensured that the effective ingredients in the medicinal materials are fully extracted to improve the efficacy; the sieving of the medicinal juice and the centrifugal filtration after concentration are helpful to separate tiny particles and impurities in the medicinal liquid, so that the medicinal liquid is clearer and more transparent; finally, the medicinal liquid after centrifugal filtration is concentrated, which can not only improve the stability of the medicinal liquid, but also facilitate the processing and storage of subsequent preparations.

[0037] As a preferred embodiment of the present technical solution, when melting the Ajiao, the Ajiao is crushed and then heated in water and stirred until the Ajiao is melted.

[0038] By melting donkey-hide gelatin, it can be prevented from adhering to other medicines or medicine pots during direct decoction, thereby reducing the loss of effective ingredients in donkey-hide gelatin. At the same time, the melting process can gently melt the donkey-hide gelatin, helping to retain the active ingredients and efficacy in the gelatin.

[0039] As a preferred embodiment of the present technical solution, when the honey is refined, the honey is heated to 116-118° C., and the water content of the honey is controlled to be 14%-16%, and the relative density is 1.3-1.4.

[0040] The honey refined in this way not only retains some of the nutritional components and medicinal value of honey, but also enhances its adhesion and stability.

[0041] In a fourth aspect, the present invention also discloses a pulmonary tuberculosis ointment prepared by the above-mentioned preparation method. When the pulmonary tuberculosis ointment is used, the pulmonary tuberculosis ointment is applied externally to the bilateral lung shu points, and then the electrode sheet of the traditional Chinese medicine ion introduction instrument is applied to the outside of the pulmonary tuberculosis ointment and pressurized, and the current intensity is controlled to be 10-20A, and the introduction time is 15-25min.

[0042] The treatment method of the present invention, which combines external application of the pulmonary tuberculosis ointment with the introduction of Chinese medicine ions, can give full play to the dual effects of drugs and physical therapy, and has the beneficial effects of combining the direct action of drugs with acupoint stimulation, the synergistic effect of the introduction of Chinese medicine ions, the advantages of specific treatment parameters, and significant comprehensive treatment effects, and significantly improves the therapeutic effect of interstitial lung diseases. Compared with oral drugs, this method can avoid drug stimulation of the gastrointestinal tract and the first-pass effect of the liver, and reduce the side effects and adverse reactions of drugs.

[0043] The Chinese medicine composition of the present invention has at least the following beneficial effects:

[0044] In the Chinese medicine composition of the present invention, firstly, according to the principle of monarch, minister, adjuvant and messenger, angelica, salvia miltiorrhiza and other blood-activating and stasis-removing drugs are selected as monarch drugs, which can improve pulmonary blood circulation, eliminate blood stasis, and relieve symptoms such as chest tightness and dyspnea caused by qi and blood stasis in interstitial lung disease; raw rehmannia, southern adenophora, northern adenophora and the like are used as ministerial drugs, which can nourish lung yin, relieve symptoms such as dry cough and little sputum caused by insufficient lung yin, assist the monarch drug to enhance the therapeutic effect, and are used to enhance the patient's immunity; ophiopogon japonicus, rehmannia glutinosa, stir-fried atractylodes macrocephala and the like are used as adjuvant drugs, which can enhance the spleen and stomach function, promote nutrient absorption, provide sufficient nutritional support for the lungs, and contribute to the recovery of lung diseases. They are also used to reconcile the medicinal properties of various drugs, enhance the overall therapeutic effect, and relieve other symptoms caused by the disease; licorice and honey and the like are used as messenger drugs, which can not only reconcile various drugs, but also have the effect of guiding the drugs to the lesion site. Secondly, according to the principle of mutual support and suitability, angelica and salvia miltiorrhiza are used together to enhance the effect of promoting blood circulation and removing blood stasis. The combination of yin-nourishing and lung-moistening drugs such as radix rehmanniae, adenophora australis, and adenophora scutellariae is used with angelica and other blood circulation and blood stasis-removing drugs, which complement each other and significantly enhance the efficacy. Finally, the drugs are carefully matched to avoid the opposite and counteracting effects between the drugs to ensure the safety and effectiveness of the drugs.

[0045] In addition, studies have shown that the Chinese medicine composition of the present invention can inhibit the activation of the PI3K / AKT signaling pathway, downregulate the expression of PI3K and AKT, reduce the expression of HIF-1α, VEGF and downstream signaling factors related to cell survival and growth, thereby inhibiting angiogenesis and delaying the development of pulmonary fibrosis.

[0046] In summary, the Chinese medicine composition of the present invention comprehensively regulates the pathogenesis of interstitial lung disease and pulmonary emphysema through reasonable compatibility principles, and has multiple effects such as promoting blood circulation and removing blood stasis, nourishing yin and moistening the lungs, strengthening the spleen and replenishing qi, clearing away heat and detoxifying, thereby delaying the development of pulmonary fibrosis. When combined with the use of a Chinese medicine ion introduction instrument, interstitial lung disease and other related diseases can be treated more effectively. BRIEF DESCRIPTION OF THE DRAWINGS

[0047] In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0048] Figure 1 The representative images of rats in the IPF model group induced by BLM of the present invention, wherein: Figure 1 (a) HE staining of lung tissues in each group after 28 days (×100); Figure 1(b) Masson staining of lung tissues in each group after 28 days (×100);

[0049] Figure 2 This is an immunofluorescence staining picture of the present invention, wherein: Figure 2 (a) DAPI staining (×200); Figure 2 (b) vWF staining (×200); Figure 2 (c) is combined staining;

[0050] Figure 3 The results of the MTT analysis used to detect cell proliferation ability in the present invention (n=6);

[0051] Figure 4 Figure 2 shows the microangiogenesis of the control group, IPF group, IPF+SQCCF group and IPF+LY294002 group (×100) ( Figure 4 (a)) and representative figure ( Figure 4 (c)), Figure 4 (b) and Figure 4 (d) The results of cell migration ability determined by Transwell analysis, (n=3), compared with the control group, **P<0.01; compared with the IPF group, ##P<0.01;

[0052] Figure 5 The results of PCR analysis of PI3K, Akt, HIF-1α and VEGF mRNA expression levels in the present invention (n=6), compared with the control group, **P<0.01; compared with the IPF group, #P<0.05. DETAILED DESCRIPTION

[0053] It should be noted that the following detailed descriptions are illustrative and are intended to provide further explanation of the present application. Unless otherwise specified, all technical and scientific terms used herein have the same meanings as those commonly understood by those skilled in the art to which the present application belongs.

[0054] It should be noted that the terms used herein are only for describing specific embodiments and are not intended to limit the exemplary embodiments according to the present application. As used herein, unless the context clearly indicates otherwise, the singular form also includes the plural form. In addition, it should be understood that when the terms "comprise" and / or "include" are used in this description, it indicates the presence of features, steps, operations, devices, components and / or combinations thereof.

[0055] The technical solution of the present invention will be clearly and completely described below in conjunction with the embodiments. Obviously, the described embodiments are part of the embodiments of the present invention, rather than all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0056] Example 1

[0057] Composition of Chinese medicine composition:

[0058] 150 parts of angelica, 100 parts of safflower, 100 parts of raw rehmannia, 100 parts of salvia miltiorrhiza, 300 parts of adenophora australis, 300 parts of northern adenophora, 100 parts of ophiopogon, 100 parts of cooked rehmannia, 100 parts of stir-fried atractylodes, 100 parts of liquorice, 300 parts of wax gourd seeds, 150 parts of knotweed, 100 parts of peach kernel, 150 parts of houttuynia cordata, 100 parts of donkey-hide gelatin, 200 parts of honey and 150 parts of crystal sugar.

[0059] Pretreatment of auxiliary materials:

[0060] Heat the honey to 116-118℃, with a water content of 14%-16%, a relative density of about 1.37, and a light red luster. During the heating process, filter out impurities with a stainless steel mesh and stir constantly to prevent sticking or overflowing.

[0061] Crush the Ajiao, heat it in water, and stir until the Ajiao is melted.

[0062] Preparation method of pulmonary tuberculosis ointment:

[0063] S1. Add water to angelica, safflower, raw rehmannia, salvia miltiorrhiza, southern adenophora, northern adenophora, ophiopogon japonicus, cooked rehmannia, stir-fried atractylodes, licorice, wax gourd seeds, knotweed, peach kernel and houttuynia cordata until the liquid surface exceeds 3-5 cm, and then soak for 10-15 hours. Boil the soaked medicinal materials together with the soaking water, filter the residue to obtain the juice 1-1.5 hours after boiling, add water to the residue to the surface of the medicine, and take the juice 1-1.5 hours after boiling. Mix the juice twice; let the mixed juice stand, pass through a 100-mesh stainless steel sieve, concentrate the filtrate to 1000 mL, centrifuge and filter, and then concentrate to obtain a clear paste with a relative density of 1.21-1.25 (80-85° C.);

[0064] S2. Add the melted Ajiao and the refined honey to the clear paste, adjust the heat appropriately, and continue heating and stirring to avoid sticking to the bottom and burning. Collect the paste to 1000mL, add crystal sugar, mix well, and obtain a paste;

[0065] S3. Immediately add the collected paste into the sterilized paste packaging machine, and pack it into 15g bags to obtain the pulmonary tuberculosis paste.

[0066] Example 2

[0067] Composition of Chinese medicine composition:

[0068] 50 parts of angelica, 100 parts of safflower, 100 parts of raw rehmannia, 100 parts of salvia miltiorrhiza, 100 parts of adenophora australis, 100 parts of northern adenophora, 100 parts of ophiopogon, 100 parts of rehmannia prepared, 100 parts of stir-fried atractylodes, 50 parts of liquorice, 100 parts of wax gourd seeds, 100 parts of knotweed, 100 parts of peach kernel, 100 parts of houttuynia cordata, 100 parts of honey, 50 parts of crystal sugar and 100 parts of donkey-hide gelatin.

[0069] Pretreatment of auxiliary materials:

[0070] Heat the honey to 116-118℃, with a water content of 14%-16%, a relative density of about 1.37, and a light red luster. During the heating process, filter out impurities with a stainless steel mesh and stir constantly to prevent sticking or overflowing.

[0071] Crush the Ajiao, heat it in water, and stir until the Ajiao is melted.

[0072] Preparation method of lung tuberculosis ointment:

[0073] S1. Add water to angelica, safflower, raw rehmannia, salvia miltiorrhiza, southern adenophora, northern adenophora, ophiopogon japonicus, cooked rehmannia, stir-fried atractylodes, licorice, wax gourd seeds, knotweed, peach kernel and houttuynia cordata until the liquid surface exceeds 3-5 cm, and then soak for 10-15 hours. Boil the soaked medicinal materials together with the soaking water, filter the residue to obtain the juice 1-1.5 hours after boiling, add water to the residue to the surface of the medicine, and take the juice 1-1.5 hours after boiling. Mix the juice twice; let the mixed juice stand, pass through a 100-mesh stainless steel sieve, concentrate the filtrate to 1000 mL, centrifuge and filter, and then concentrate to obtain a clear paste with a relative density of 1.21-1.25 (80-85° C.);

[0074] S2. Add the melted Ajiao and the refined honey to the clear paste, adjust the heat appropriately, and continue heating and stirring to avoid sticking to the bottom and burning. Collect the paste to 1000mL, add crystal sugar, mix well, and obtain a paste;

[0075] S3. Immediately add the collected paste into the sterilized paste packaging machine, and pack it into 15g bags to obtain the pulmonary tuberculosis paste.

[0076] Example 3

[0077] Composition of Chinese medicine composition:

[0078] 150 parts of angelica, 200 parts of safflower, 300 parts of raw rehmannia, 300 parts of salvia miltiorrhiza, 300 parts of adenophora australis, 300 parts of northern adenophora, 200 parts of ophiopogon, 300 parts of cooked rehmannia, 300 parts of stir-fried atractylodes, 150 parts of liquorice, 300 parts of wax gourd seeds, 300 parts of knotweed, 200 parts of peach kernel, 300 parts of houttuynia, 300 parts of honey, 150 parts of crystal sugar and 200 parts of donkey-hide gelatin.

[0079] Pretreatment of auxiliary materials:

[0080] Heat the honey to 116-118℃, with a water content of 14%-16%, a relative density of about 1.37, and a light red luster. During the heating process, filter out impurities with a stainless steel mesh and stir constantly to prevent sticking or overflowing.

[0081] Crush the Ajiao, heat it in water, and stir until the Ajiao is melted.

[0082] Preparation method of lung tuberculosis ointment:

[0083] S1. Add water to angelica, safflower, raw rehmannia, salvia miltiorrhiza, southern adenophora, northern adenophora, ophiopogon japonicus, cooked rehmannia, stir-fried atractylodes, licorice, wax gourd seeds, knotweed, peach kernel and houttuynia cordata until the liquid surface exceeds 3-5 cm, and then soak for 10-15 hours. Boil the soaked medicinal materials together with the soaking water, filter the residue to obtain the juice 1-1.5 hours after boiling, add water to the residue to the surface of the medicine, and take the juice 1-1.5 hours after boiling. Mix the juice twice; let the mixed juice stand, pass through a 100-mesh stainless steel sieve, concentrate the filtrate to 1000 mL, centrifuge and filter, and then concentrate to obtain a clear paste with a relative density of 1.21-1.25 (80-85° C.);

[0084] S2. Add the melted Ajiao and the refined honey to the clear paste, adjust the heat appropriately, and continue heating and stirring to avoid sticking to the bottom and burning. Collect the paste to 1000mL, add crystal sugar, mix well, and obtain a paste;

[0085] S3. Immediately add the collected paste into the sterilized paste packaging machine, and pack it into 15g bags to obtain the pulmonary tuberculosis paste.

[0086] Test Example 1

[0087] Animal experiment data

[0088] Materials and methods

[0089] Reagents and medicines

[0090] Select 15g of Angelica sinensis, 10g of Rehmannia glutinosa, 10g of Salvia miltiorrhiza, 30g of Adenophora australis, 30g of Glehnia littoralis, 10g of Ophiopogon japonicus, 10g of Rehmannia glutinosa, 10g of Stir-fried Atractylodes macrocephala, 10g of Licorice root, 30g of Wax gourd seeds, 15g of Polygonum cuspidatum and 10g of Peach kernel for the following animal experiment.

[0091] Bleomycin (1935037) was purchased from Invitrogen and prepared into a 5 mg / ml solution in physiological saline for later use and stored in a refrigerator at 4°C;

[0092] Goat anti-Rabbit IgG (H+L) Cross-Adsorbed Secondary antibody, AlexaFluor 488 (SA00006-2) was purchased from proteintech (CHI, USA);

[0093] LY294002 solution was purchased from Biyuntian (Shanghai, China);

[0094] Ttypsin-EDTA (0.25%) (25200056) was purchased from Gibco (Grand Island, NY, USA);

[0095] Fluoromount-G (0100-01) was purchased from SouthernBiotech (Beijing, China);

[0096] TRIzol Reagent (15596018) was purchased from Life technogies (Shanghai, China);

[0097] Endothelial cell-specific culture medium (CM-R001) was purchased from Procell (Wuhan, China);

[0098] The reverse transcription kit PrimeScript TMRT reagent Kit with gDNA Eraser (RR047A) was purchased from Takara (Beijing, China).

[0099] animal

[0100] 60 SPF SD male rats with a body weight of 220 ± 20 were obtained. They were provided by Jinan Pengyue, license number: SCXK (Lu) 20190003. The rats were housed in the animal room of the Experimental Center of Anhui Provincial Hospital of Traditional Chinese Medicine. The animal room was well ventilated, with acceptable temperature and humidity, a light-dark cycle of 12am / 12pm, and regular feeding, watering, and bedding changes. Relevant experimental studies were conducted after 7 days of adaptive feeding.

[0101] Modeling

[0102] Twenty rats were selected and randomly divided into two groups: a blank group and an IPF model group. After 7 days of adaptive feeding, a one-time intratracheal instillation of bleomycin solution was used to establish the model. That is, the rats in the IPF model group were anesthetized by intraperitoneal injection of 3% sodium pentobarbital (30 mg / kg), fixed on a rat board, the hair in the middle of the rat neck was shaved, disinfected, and the trachea was exposed. A 1 ml syringe was used to slowly inject bleomycin (BLM, 3.5 mg / kg) with a concentration of 5 mg / ml into the tracheal cartilage space. After the injection, the rats were quickly stood upright and rotated several times to ensure that the drug solution could be evenly distributed in the lung tissue, and the layers were sutured in turn, and the surgical wounds were disinfected. The rats were fully awake in a dry cage and continued to be fed for 28 days. The blank group rats were instilled with an equal amount of normal saline. The two groups of rats were closely monitored daily and the survival and death of the rats were recorded.

[0103] Preparation of the above-mentioned Chinese medicine composition prescription containing serum

[0104] 40 rats were selected and randomly divided into two groups: a blank serum group and a drug-containing serum group. After 7 days of adaptive feeding, the rats in the drug-containing serum group were gavaged with the above-mentioned Chinese medicine composition prescription (0.38 g / kg per day, equivalent to 7 times the adult dose). Rats in the blank serum group were gavaged with an equal amount of normal saline twice a day for 3 consecutive days. One hour after the second administration on the third day, 3% sodium pentobarbital (30 mg / kg) was given intraperitoneal anesthesia. After anesthesia, blood was collected from the abdominal aorta of the rats. After blood collection, the blood was centrifuged at 3000 rpm, complement was inactivated in a water bath, mixed in the same group, sterilized by 0.22 μL filter membrane, vacuum dried at low temperature for 48 hours, and the dried powder was sealed and stored at minus 20°C.

[0105] Lung histopathological staining

[0106] After 28 days, the blank group and IPF model group were killed, the lungs were removed aseptically, the lung lobes were separated, and the left lower lobe was immersed in 10% formalin solution. After routine pathological treatment such as dehydration, embedding, and sectioning, HE and Masson staining were performed, and the pathological changes of lung tissue were observed under an optical microscope. Other lung tissues were stored in PBS solution at low temperature for further experiments.

[0107] Preparation and identification of PMVECs:

[0108] Cell preparation: Take the lung tissue stored above, rinse it 3 times with PBS, and remove other connective tissues. Cut the lung tissue into blocks of about 1 mm in size, and wash the tissue blocks 3 times with PBS (containing double antibody). Distribute the tissue blocks evenly in the cell culture bottle, and cling to the inner wall of the cell culture bottle. Add an appropriate amount of endothelial cell culture fluid, place the cell culture bottle containing the tissue in the incubator and culture for 48 hours. After 48 hours, change the cell culture fluid, clean the tissue blocks, and then change the cell culture fluid every 48 hours until the endothelial cells converge and cover the entire cell culture bottle.

[0109] Cell identification: Take 3 glass slides and place them in a 24-well plate. Add 1 ml of culture medium to each well, add 0.02×107 cells / well, and incubate for 2 hours. After the cells crawl, aspirate the culture medium, rinse with PBS, fix with 4% PFA at 4℃ for 30 minutes, and wash again with PBS for 3×5 minutes / time. Incubate overnight at 4℃. Incubate the cells with 0.5% Trition X-100 (PBS 1:1 dilution) for 2 hours. Discard the blocking solution, add the antibody (PBS 1:100 dilution) and incubate in a wet box at 4℃. After incubating the secondary antibody (PBS 1:500 dilution) at room temperature in the dark for 2 hours, rinse with PBS 3 times, add DAPI (PBS 1:1000 dilution) and counterstain at room temperature for 5 minutes, rinse with PBS again, add the mounting medium Fluoromount-G3 to mount the slide, and examine with a fluorescence microscope.

[0110] MTT assay for PMVECs proliferation in IPF rats and screening of optimal serum concentration of SQCCF

[0111] After 12 hours of incubation at room temperature, the cells were divided into five groups:

[0112] Group A: blank group rat pulmonary microvascular endothelial cells (cultured with blank serum for 2 days);

[0113] Group B: Pulmonary microvascular endothelial cells of rats in the IPF model group (cultured with blank serum for 2 days);

[0114] Group C: Pulmonary microvascular endothelial cells of rats in the IPF model group + 5% drug-containing serum (cultured with 5% drug-containing serum for 2 days);

[0115] Group D: Pulmonary microvascular endothelial cells of rats in the IPF model group + 10% drug-containing serum (cultured with 10% drug-containing serum for 2 days);

[0116] Group E: Pulmonary microvascular endothelial cells of rats in the IPF model group + 20% drug-containing serum (added with 20% drug-containing serum for 2 days).

[0117] Add 10 μl of MTT solution (5 mg / ml) to each well and culture for 4 hours; after the crystals are completely formed and the supernatant is removed, add 150 μl of dimethyl sulfoxide to each well and shake the plate on a shaker for 10 minutes. At the same time, set the zeroing well (culture medium, MTT and dimethyl sulfoxide). The calculation formula for cell survival rate is (%) = (experimental well-zeroing well) / (control well-zeroing well); the blank group is set as the control well.

[0118] Identification of the luminal behavior of PMVECs in IPF rats by the serum containing the above-mentioned Chinese medicine combination prescription:

[0119] The cells were digested with 0.25% trypsin (containing 0.02% EDTA) to prepare a cell suspension, centrifuged at 1000 rpm for 5 min, the supernatant was discarded, and the cells were resuspended in a special culture medium (CM-R001) at a rate of 2×10 5 Rat pulmonary vascular endothelial cells were seeded into 6-well plates / well and cultured overnight.

[0120] According to different experimental interventions, cells were divided into 5 groups:

[0121] Group A: blank group rat pulmonary vascular endothelial cells;

[0122] Group B: pulmonary vascular endothelial cells of rats in IPF model group;

[0123] Group C: Pulmonary vascular endothelial cells of rats in the IPF model group + 10% drug-containing serum (10% drug-containing serum was added and cultured for another 24 hours, and the MTT test results showed that 10% drug-containing serum of the above-mentioned Chinese medicine combination prescription was the optimal concentration);

[0124] Group D: Pulmonary vascular endothelial cells of rats in the IPF model group + PI3K inhibitor (1.4 μmol / L of PI3K inhibitor was added and cultured for another 24 h);

[0125] Group E: IPF model group rat pulmonary vascular endothelial cells + 10% drug-containing serum + PI3K inhibitor (PI3K inhibitor 1.4umol / L + 10% drug-containing serum were added and cultured for another 24h);

[0126] The pre-cooled matrix gel was placed in a 48-well plate, 100 μl of matrix gel was added to each well and evenly spread over the well, and the plate was placed in a 37°C incubator for 1 hour. 5 100 μg / well were added to a 48-well plate. After 6 hours, the cells were taken out and three fields of view were randomly selected under an inverted phase contrast microscope to observe the tubule formation.

[0127] RT-qPCR was used to detect the relative expression of PI3K mRNA, AKT mRNA, HIF-1α mRNA and VEGF mRNA

[0128] The cells of group A, group B, group C, group D, and group E cultured in the above experiment were divided into five groups: control group (K), model group (MX), 10% drug-containing serum group (SY), PI3K inhibitor group (YZ), and 10% drug-containing serum + PI3K inhibitor group (SYYZ). Total RNA of cells in each group was extracted strictly according to the instructions of the RT-qPCR kit, and cDNA was synthesized by reverse transcription reaction with random primers for RT-qPCR.

[0129] The primers used in PCR were synthesized by Sangon Biotech, and the primer sequences are as follows:

[0130] β-actin: 5′-CCCATCTATGAGGGTTACGC-3′ and 5′-TTTAATGTCACGCACGATTTC-3′;

[0131] AKT: 5′-CAGGTTCACCCAGTGACAAC-3′ and 5′-CTCCTTCACCAGGATCACCT-3′;

[0132] PI3Kp85α: 5′-CGAAACAAAGCCGAGAACCT-3′ and 5′-GACGCAATGTTTGACTTCGC-3′;

[0133] VEGF: 5′-TTGAGACCCTGGTGGACATC-3′ and 5′-CTCCAGGGGCTTCATCATTGC-3′;

[0134] HIF-1α: 5′-TGACCACTGCTAAGGCATCA-3′ and 5′-GGCTCCTTGGATGAGCTTTG-3.

[0135] Adoption 2 -△△Ct The relative expression levels of PI3K mRNA, AKT mRNA, HIF-1α mRNA and VEGF mRNA in each group of cells were calculated by the method.

[0136] Statistical methods

[0137] Data analysis was performed using IBM SPSS Statistics 25 (IBM Corp., Armonk, NY, USA). Quantitative data (x ± y) were analyzed using one-way analysis of variance between groups, and two-way comparisons between groups were performed with the lowest significance. If the data were not normally distributed or the variances were unequal, nonparametric tests were used, and P-value < 0.05 was considered statistically significant.

[0138] Experimental Results

[0139] 1. Survival and mortality of the four groups of rats and evaluation of BLM-induced lung tissue damage

[0140] After tracheal instillation of BLM, the mortality rate of rats in the IPF model group was 20% within 28 days, which may be related to the progression of pulmonary fibrosis. No rats died in the blank group, blank serum group, and drug-containing serum group, and the rats had good appetite, normal breathing, good spirits, and high activity. However, the rats in the IPF model group gradually ate less and drank less, had weak spirits, dull fur, panting, and reduced activity.

[0141] HE staining can be used to observe changes in the tissue structure of lung tissue. Figure 1As shown in (a), the alveolar morphology of rats in the blank group was normal, without edema, inflammatory cell infiltration, and collagen deposition; while edema and inflammatory cell infiltration were observed in the alveolar septa of rats in the model group, and collagen fiber deposition was observed.

[0142] Masson staining can be used to observe the collagen fibers in lung tissue. After staining, the collagen fibers can be dyed blue. This result can be used to evaluate the degree of lung tissue fibrosis. Figure 1 As shown in (b), the alveolar structure of rats in the blank group was normal, with no blue-stained area around the alveoli, no collagen deposition, and no infiltrating inflammatory cells; in the IPF model group, a large number of blue-stained deposited collagen fibers were observed around the vascular walls and tracheal walls.

[0143] HE staining and Masson staining showed that the BLM-induced fibrosis model was successful and the next experiment could be carried out.

[0144] 2. PMVECs identification

[0145] After DAPI and vWF staining, the nuclei of cells in the IPF model group were blue ( Figure 2 a), cytoplasm is green ( Figure 2 b), combined staining Figure 2 c, showing positive expression of vWF. PMVECs are a key source of cytokines that promote pulmonary fibrosis. Von Willebrand factor (vWF) is strongly expressed in PMVECs and is a specific marker, indicating that the cells obtained from this cell crawling are the target cells, and the purity of PMVECs is more than 90%, so the next step of the experiment can be carried out.

[0146] 3. Effect of SQCCF on the proliferation of PMVECs

[0147] The MTT assay was used to determine the effects of different concentrations of the above-mentioned Chinese medicine combination formula (SQCCF) on the proliferation activity of PM VECs. The results were also used to select the optimal concentration of drug-containing serum for subsequent experiments ( Figure 3 ).

[0148] The results showed that the cell proliferation activity of the model group was significantly improved compared with the control group (P<0.01). Compared with the IPF model group, the addition of 5% drug-containing serum had no significant effect on cell proliferation activity (P>0.05), while the addition of 10% and 20% drug-containing serum had a significant inhibitory effect on cell proliferation activity (P<0.01), and the inhibitory effect of 10% drug-containing serum was stronger than that of 20% (P<0.05). Therefore, 10% drug-containing serum was selected for subsequent experiments.

[0149] 4. Effect of SQCCF on PMVECs Migration

[0150] In order to verify the effect of serum containing SQCCF on PMVECs migration, PMVECs (>90% purity) were inoculated with matrix gel. Group A: microangiogenesis of PMVECs in rats in the blank group (×100); Group B: microangiogenesis of PMVECs in rats in the IPF model group (×100); C: microangiogenesis of PMVECs in rats in the IPF model group co-cultured with 10% drug-containing serum (×100); Group D: microangiogenesis of PMVECs in rats co-cultured with PI3K inhibitor (LY294002) (×100).

[0151] Figure 4 (a) shows that cells adhere to the wall to form a cavity-like structure, and the monolayer cells gather around the wall and mix to form a network structure with connections similar to a "honeycomb". However, the number of PMVEC tubules formed in each group was different due to different pretreatment methods. Figure 4 (b) As shown, there was a certain amount of basal expression of tubules in group A; the number of tubules formed in group B was significantly higher than that in group A (P<0.01), suggesting that the main pathological change of IPF is angiogenesis, leading to abnormal lung remodeling; the number of tubules formed in groups C and D was lower than that in group B (P<0.05). Three 100× fields of view were randomly selected for each group ( Figure 4 a,b)

[0152] The results also showed that both drug-containing serum and PI3K inhibitors can inhibit the expression of pulmonary tubules, thereby inhibiting angiogenesis, delaying lung tissue remodeling, and prolonging the progression of pulmonary fibrosis. To further confirm that serum containing SQ CCF affects the migration of PMVECs, we conducted an experiment showing that the number of migrating PMVECs in the IPF group increased significantly (P<0.01), while 10% SQCCF-containing serum and LY294002 treatment both inhibited the migration of PMVECs (P<0.01). These results are consistent with the results of the tubule formation experiment, which indicates that SQCCF can inhibit the migration of PMVECs and the migration of new blood vessels, thereby delaying pulmonary fibrosis by reducing the migration of PMVECs. Three views were randomly selected from each group ( Figure 4 c, d).

[0153] 5. Inhibition of the expression of PMVECs signaling molecules by SQCCF

[0154] To investigate the relevance of the PI3K / AKT signaling pathway in IPF angiogenesis, the expression levels of PI3K, AKT, and downstream factors in PM VECs were detected.

[0155] Western blot and qRT-PCR results showed that ( Figure 5), the mRNA and protein expressions of PI 3K and AKT in the IPF group were significantly increased after SQCCF treatment. HIF-1α and VEGF are important downstream factors of the PI3K / AKT signaling pathway that mediates angiogenesis. Therefore, the present invention further detected the expression of HIF-1α and VEGF mRNA. The results showed that the expression of HIF-1α and VEGF mRNA in the IPF group was significantly increased. In addition, after SQCCF or LY294002 treatment, the expression of HIF-1α and VEGF decreased.

[0156] The results showed that SQCCF could inhibit the activation of the PI3K / AKT signaling pathway, downregulate the expression of PI3K and AKT, reduce the expression of HIF-1α, VEGF, and downstream signaling factors related to cell survival and growth, thereby inhibiting angiogenesis and delaying the development of pulmonary fibrosis.

[0157] Test Example 2

[0158] Clinical application data

[0159] The pulmonary tuberculosis ointment of the present invention has been used to treat more than 100 patients with interstitial lung disease, pulmonary tuberculosis and other lung diseases, with a total effective rate of more than 90%. Due to the privacy of patients, it is not convenient to provide specific information here.

[0160] In summary, the Chinese medicine composition of the present invention can comprehensively regulate the pathogenesis of interstitial lung disease and pulmonary emphysema through reasonable compatibility principles, thereby delaying the development of pulmonary fibrosis. When combined with the use of a Chinese medicine ion introduction instrument, it can more effectively treat interstitial lung disease and other related diseases.

[0161] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.

Claims

1. A Chinese medicine composition, characterized in that: The invention comprises the following raw materials in parts by weight: 50-150 parts of angelica sinensis, 100-300 parts of raw rehmannia, 100-300 parts of salvia miltiorrhiza, 100-300 parts of adenophora australis, 100-300 parts of northern adenophora, 100-200 parts of ophiopogon japonicus, 100-300 parts of cooked rehmannia, 100-300 parts of stir-fried atractylodes, 50-150 parts of liquorice, 100-300 parts of wax gourd seeds, 100-300 parts of knotweed, and 100-200 parts of peach kernel.

2. The Chinese medicine composition according to claim 1, characterized in that: The invention comprises the following raw materials in parts by weight: 100-200 parts of safflower, 100-300 parts of houttuynia cordata, 100-300 parts of honey, 50-150 parts of crystal sugar and 100-200 parts of donkey-hide gelatin.

3. The Chinese medicine composition according to claim 1, characterized in that The invention comprises the following raw materials in parts by weight: 150 parts of angelica, 100 parts of safflower, 100 parts of raw rehmannia, 100 parts of salvia miltiorrhiza, 300 parts of adenophora australis, 300 parts of northern adenophora, 100 parts of ophiopogon, 100 parts of cooked rehmannia, 100 parts of stir-fried atractylodes, 100 parts of liquorice, 300 parts of wax gourd seeds, 150 parts of knotweed, 100 parts of peach kernel, 150 parts of houttuynia cordata, 100 parts of donkey-hide gelatin, 200 parts of honey and 150 parts of crystal sugar.

4. Use of the Chinese medicine composition according to any one of claims 1 to 3 in the preparation of an anti-pulmonary disease medicament, characterized in that: The anti-pulmonary disease includes interstitial lung disease, and the medicament includes drugs and health products.

5. The use according to claim 4, characterized in that: The types of the medicament include decoction, suspension, paste, granule, pill, powder, tablet or capsule.

6. A method for preparing a pulmonary tuberculosis ointment, characterized in that: The following steps are involved: S1, soaking angelica, safflower, raw rehmannia, salvia miltiorrhiza, adenophora australis, adenophora scabra, ophiopogon japonicus, cooked rehmannia, stir-fried atractylodes macrocephala, liquorice, wax gourd seeds, knotweed, peach kernel and houttuynia cordata in water, decocting, concentrating and filtering to obtain a clear paste; S2, adding melted ajiao and refined honey to the clear paste, collecting the paste and adding crystal sugar to obtain a paste; S3. Add the paste into the paste packaging machine and divide it into packages to obtain the pulmonary tuberculosis paste.

7. The preparation method according to claim 6, characterized in that: During the soaking, water is added to the Chinese medicinal materials until the water level exceeds the medicinal materials by 3-5 cm, and then the water is soaked for 10-15 hours; During the decoction, the soaked medicinal materials are decocted together with the soaking water, the residue is filtered out 1-1.5 hours after boiling to obtain the medicinal juice, water is added to the residue until the medicinal surface is reached, the medicinal juice is obtained 1-1.5 hours after boiling, and the two medicinal juices are mixed; the mixed medicinal juice is allowed to stand and sieved, and the obtained filtrate is concentrated to 1000 mL, centrifuged and filtered, and then concentrated to obtain a clear paste with a relative density of 1.21-1.

25.

8. The preparation method according to claim 6, characterized in that: When the Ajiao is melted, the Ajiao is crushed and heated in water, and stirred until the Ajiao is melted.

9. The preparation method according to claim 6, characterized in that: During the honey refining, the honey is heated to 116-118° C., and the water content of the honey is controlled to be 14%-16%, and the relative density is 1.3-1.

4.

10. A pulmonary tuberculosis ointment, characterized in that: The preparation method according to any one of claims 6 to 9 is used to prepare the pulmonary tuberculosis ointment, which is applied externally to the bilateral lung shu points, and then the electrode sheet of the traditional Chinese medicine ion introduction instrument is applied to the outside of the pulmonary tuberculosis ointment and pressurized, and the current intensity is controlled to be 10-20A, and the introduction time is 15-25min.

Images